Millennium Management LLC Has $145,000 Stake in BrainsWay Ltd. (NASDAQ:BWAY)

Millennium Management LLC reduced its stake in shares of BrainsWay Ltd. (NASDAQ:BWAY) by 34.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 15,366 shares of the company’s stock after selling 8,008 shares during the quarter. Millennium Management LLC owned approximately 0.08% of BrainsWay worth $145,000 as of its most recent filing with the SEC.

Several other large investors have also recently added to or reduced their stakes in BWAY. Phoenix Financial Ltd. increased its stake in shares of BrainsWay by 100.8% in the fourth quarter. Phoenix Financial Ltd. now owns 482,724 shares of the company’s stock worth $4,552,000 after acquiring an additional 242,366 shares during the last quarter. ARK Investment Management LLC purchased a new stake in shares of BrainsWay during the 4th quarter worth about $1,656,000. MYDA Advisors LLC lifted its holdings in shares of BrainsWay by 100.2% during the 4th quarter. MYDA Advisors LLC now owns 120,100 shares of the company’s stock valued at $1,133,000 after buying an additional 60,100 shares during the last quarter. Zuckerman Investment Group LLC grew its stake in shares of BrainsWay by 346.4% in the 4th quarter. Zuckerman Investment Group LLC now owns 67,000 shares of the company’s stock valued at $667,000 after buying an additional 51,991 shares in the last quarter. Finally, Sei Investments Co. bought a new position in BrainsWay during the fourth quarter valued at approximately $149,000. Institutional investors and hedge funds own 30.11% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $16.00 price target on shares of BrainsWay in a research note on Monday.

BrainsWay Stock Down 2.6%

Shares of BrainsWay stock opened at $11.42 on Friday. BrainsWay Ltd. has a 12-month low of $5.67 and a 12-month high of $12.00. The stock has a 50 day moving average price of $9.46 and a two-hundred day moving average price of $9.79. The stock has a market capitalization of $215.64 million, a P/E ratio of 114.21 and a beta of 1.32.

BrainsWay (NASDAQ:BWAY) last released its earnings results on Tuesday, May 13th. The company reported $0.04 earnings per share for the quarter, topping analysts’ consensus estimates of $0.02 by $0.02. BrainsWay had a net margin of 3.88% and a return on equity of 3.52%. The firm had revenue of $11.54 million during the quarter, compared to analyst estimates of $11.45 million. Sell-side analysts anticipate that BrainsWay Ltd. will post 0.08 earnings per share for the current year.

About BrainsWay

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.